Condition: Patient Population With Multivessel Disease · Sponsor: Sahajanand Medical Technologies Limited
The primary objective of this registry is to evaluate the safety and clinical performance of the biodegradable polymer-coated Supraflex Cruz Sirolimus-eluting Stent (SES) in an unselected, all-comer patient population with multivessel disease. This population represents daily clinical practice and includes patients requiring coronary revascularization with drug-eluting stents (DES).
This description comes directly from the study's public registry record.
Prof. Nadhem HAJLAOUI · +216 55130873 · drnadhemhajlaoui@gmail.com
Always discuss trial participation with your own doctor first.
| Sahloul Hospital | Sousse, Tunisia | Recruiting |
| Habib Thameur Hospital | Tunis, Tunisia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06663696